Mitochondrial Dysfunction in the Pathogenesis of Parkinson Disease: Current Concepts and Potential Therapeutic Strategies

Cover Page

Cite item

Full Text

Abstract

Parkinson disease (PD) is a progressive extrapyramidal disorder characterized by the biodegradation of dopaminergic neurons in the substantia nigra. The total number of patients diagnosed with PD worldwide is expected to more than double by 2030, inevitably placing a significant financial burden on healthcare systems. The progression of the disease leads to persistent maladjustment in all aspects of the patient’s life, resulting in a loss of human resources. Approximately 85–90% of PD cases are sporadic and multifactorial. The remaining 10–15% are familial forms with conventional inheritance patterns. Current research suggests multiple mechanisms for PD development, but increasing evidence supports a critical role of mitochondrial dysfunction in PD pathogenesis.

The aim of this review was to discuss the key pathogenetic mechanisms of mitochondrial dysfunction in PD pathogenesis. The following keywords and phrases (both in Russian and English) were used to search databases such as eLIBRARY.RU, PubMed, and Web of Science for full-text articles in Russian and English published over the last 20 years: Parkinson disease, neurodegeneration, pathophysiology, mitochondrial dysfunction, bioenergetics, mitophagy, pathogenetic therapy.

The review describes the factors that cause mitochondrial dysfunction and its impact on PD. Potential therapeutic strategies targeting mitochondrial dysfunction are also described.

About the authors

Natalia G. Zhukova

Siberian State Medical University

Email: sayfutdinxodjaev2002@gmail.com
ORCID iD: 0000-0001-6547-6622

Dr. Sci. (Med.), Professor, Professor, Department of neurology and neurosurgery

Russian Federation, 2, Moskovsky tract, Tomsk, 634050

Julia V. Kolobovnikova

Siberian State Medical University

Email: sayfutdinxodjaev2002@gmail.com
ORCID iD: 0000-0001-7156-2471

Dr. Sci. (Med.), Associate Professor, Dean, Faculty of medicine and biology, Head, Department of normal physiology, Professor, Department of pathophysiology

Russian Federation, 2, Moskovsky tract, Tomsk, 634050

Zaynutdinkhuzha F. Sayfitdinkhuzhaev

Siberian State Medical University

Author for correspondence.
Email: sayfutdinxodjaev2002@gmail.com
ORCID iD: 0009-0007-2184-2708
SPIN-code: 9065-3080

research assistant, Department of scientific and educational laboratory of cognitive neurophysiology of psychosomatic relationships

Russian Federation, 2, Moskovsky tract, Tomsk, 634050

References

  1. Зарипов Н.А., Додхоев Д.С., Абдуллозода С.М., Джамолова Р.Д. Немоторные симптомы болезни Паркинсона. Вестник Авиценны. 2021;23(3):342–351. Zaripov NA, Dodxoev DS, Abdullzoda SM, Zhamalova RD. Nonmotor clinic Parkinson’s disease. Avicenna’s Bulletin. 2021;23(3):342–351. doi: 10.25005/2074-0581-2021-23-3-342-351
  2. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–386. doi: 10.1212/01.wnl.0000247740.47667.03
  3. Катунина Е.А., Бездольный Ю.Н. Эпидемиология болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;113(12):81–88. Katunina EA, Bezdolniy YuN. Epidemiology of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(12):81–88.
  4. Polito L, Greco A, Seripa D. Genetic profile, environmental exposure, and their interaction in Parkinson’s disease. Parkinsons Dis. 2016;2016:6465793. doi: 10.1155/2016/6465793
  5. Zaltieri M, Longhena F, Pizzi M, et al. Mitochondrial dysfunction and α-synuclein synaptic pathology in Parkinson’s disease: who’s on first? Parkinsons Dis. 2015;2015:108029. doi: 10.1155/2015/108029
  6. Hauser DN, Hastings TG. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease and monogenic parkinsonism. Neurobiol Dis. 2013;51:35–42. doi: 10.1016/j.nbd.2012.10.011
  7. Esteves AR, Arduíno DM, Swerdlow RH, et al. Oxidative stress involvement in alpha-synuclein oligomerization in Parkinson’s disease cybrids. Antioxid Redox Signal. 2009;11(3):439–448. doi: 10.1089/ars.2008.2247
  8. Blesa J, Przedborski S. Parkinson’s disease: animal models and dopaminergic cell vulnerability. Front Neuroanat. 2014;8:155. doi: 10.3389/fnana.2014.00155
  9. Lindholm D, Mäkelä J, Di Liberto V, et al. Current disease modifying approaches to treat Parkinson’s disease. Cell Mol Life Sci. 2016;73(7):1365–1379. doi: 10.1007/s00018-015-2101-1
  10. Mustapha M, Mat Taib CN. MPTP-induced mouse model of Parkinson’s disease: a promising direction of therapeutic strategies. Bosn J Basic Med Sci. 2021;21(4):422–433. doi: 10.17305/bjbms.2020.5181
  11. Freire C, Koifman S. Pesticide exposure and Parkinson’s disease: epidemiological evidence of association. Neurotoxicology. 2012;33(5):947–971. doi: 10.1016/j.neuro.2012.05.011
  12. Inden M, Kitamura Y, Abe M, et al. Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL/6 mice. Biol Pharm Bull. 2011;34(1):92+96. doi: 10.1248/bpb.34.92
  13. Pozo Devoto VM, Falzone TL. Mitochondrial dynamics in Parkinson’s disease: a role for α-synuclein? Dis Model Mech. 2017;10(9):1075–1087. doi: 10.1242/dmm.026294
  14. Park JS, Davis RL, Sue CM. Mitochondrial dysfunction in Рarkinson’s disease: new mechanistic insights and therapeutic perspectives. Curr Neurol Neurosci Rep. 2018;18(5):21. doi: 10.1007/s11910-018-0829-3
  15. Chu Y, Goldman JG, Kelly L., et al. Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson’s disease. Neurobiol Dis. 2014;69:1–14. doi: 10.1016/j.nbd.2014.05.003
  16. Perfeito R, Cunha-Oliveira T, Rego AC. Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse. Free Radic Biol Med. 2012;53(9):1791–1806. doi: 10.1016/j.freeradbiomed.2012.08.569
  17. Ganguly G, Chakrabarti S, Chatterjee U, Saso L. Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer’s disease and Parkinson’s disease. Drug Des Devel Ther. 2017;11:797–810. doi: 10.2147/DDDT.S130514
  18. Carboni E., Lingor P. Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson’s disease. Metallomics. 2015;7(3):395–404. doi: 10.1039/c4mt00339j
  19. Carboni E, Lingor P. Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson’s disease. Metallomics. 2015;7(3):395–404. doi: 10.1039/c4mt00339j
  20. Muñoz Y, Carrasco CM, Campos JD, et al. Parkinson’s disease: the mitochondria-iron link. Parkinsons Dis. 2016;2016:7049108. doi: 10.1155/2016/7049108
  21. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276(5321):2045–2047. doi: 10.1126/science.276.5321.2045
  22. Mullin S, Schapira A. α-Synuclein and mitochondrial dysfunction in Parkinson’s disease. Mol Neurobiol. 2013;47(2):587–597. doi: 10.1007/s12035-013-8394-x
  23. Ryan BJ, Hoek S, Fon EA, Wade-Martins R. Mitochondrial dysfunction and mitophagy in Parkinson’s: from familial to sporadic disease. Trends Biochem Sci. 2015;40(4):200–210. doi: 10.1016/j.tibs.2015.02.003
  24. Guardia-Laguarta C, Area-Gomez E, Rüb C, et al. α-Synuclein is localized to mitochondria-associated ER membranes. J Neurosci. 2014;34(1):249–259. doi: 10.1523/JNEUROSCI.2507-13.2014
  25. Paillusson S, Gomez-Suaga P, Stoica R, et al. α-Synuclein binds to the ER-mitochondria tethering protein VAPB to disrupt Ca2+ homeostasis and mitochondrial ATP production. Acta Neuropathol. 2017;134(1):129–149. doi: 10.1007/s00401-017-1704-z
  26. Ryan SD, Dolatabadi N, Chan SF, et al. Isogenic human iPSC Parkinson’s model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription. Cell. 2013;155(6):1351–1364. doi: 10.1016/j.cell.2013.11.009
  27. Yue M, Hinkle KM, Davies P, et al. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis. 2015;78:172–195. doi: 10.1016/j.nbd.2015.02.031
  28. Reinhardt P, Schmid B, Burbulla LF, et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell. 2013;12(3):354–367. doi: 10.1016/j.stem.2013.01.008
  29. Santos D, Esteves AR, Silva DF, et al. The Impact of mitochondrial fusion and fission modulation in sporadic Parkinson’s disease. Mol Neurobiol. 2015;52(1):573–586. doi: 10.1007/s12035-014-8893-4
  30. Papkovskaia TD, Chau KY, Inesta-Vaquera F, et al. G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. Hum Mol Genet. 2012;21(19):4201–4213. doi: 10.1093/hmg/dds244
  31. Hsieh CH, Shaltouki A, Gonzalez AE, et al. functional impairment in Miro degradation and mitophagy is a shared feature in familial and sporadic Parkinson’s disease. Cell Stem Cell. 2016;19(6):709–724. doi: 10.1016/j.stem.2016.08.002
  32. Vilariño-Güell C, Wider C, Ross OA, et al. VPS35 mutations in Parkinson disease. Am J Hum Genet. 2011;89(1):162–167. doi: 10.1016/j.ajhg.2011.06.001
  33. Zimprich A, Benet-Pagès A, Struhal W, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet. 2011;89(1):168–175. doi: 10.1016/j.ajhg.2011.06.008
  34. Small SA, Petsko GA. Retromer in Alzheimer disease, Parkinson disease and other neurological disorders. Nat Rev Neurosci. 2015;16(3):126–132. doi: 10.1038/nrn3896
  35. Bi F, Li F, Huang C, Zhou H. Pathogenic mutation in VPS35 impairs its protection against MPP(+) cytotoxicity. Int J Biol Sci. 2013;9(2):149–155. doi: 10.7150/ijbs.5617
  36. Tang FL, Liu W, Hu JX, et al. VPS35 deficiency or mutation causes dopaminergic neuronal loss by impairing mitochondrial fusion and function. Cell Rep. 2015;12(10):1631–1643. doi: 10.1016/j.celrep.2015.08.001
  37. Wang W, Wang X, Fujioka H, et al. Parkinson’s disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes. Nat Med. 2016;22(1):54–63. doi: 10.1038/nm.3983
  38. Chou L, Wang W, Hoppel C, et al. Parkinson’s disease-associated pathogenic VPS35 mutation causes complex I deficits. Biochim Biophys Acta Mol Basis Dis. 2017;1863(11):2791–2795. doi: 10.1016/j.bbadis.2017.07.032
  39. Funayama M, Ohe K, Amo T, et al. CHCHD2 mutations in autosomal dominant late-onset Parkinson’s disease: a genome-wide linkage and sequencing study. Lancet Neurol. 2015;14(3):274–282. doi: 10.1016/S1474-4422(14)70266-2
  40. Aras S, Bai M, Lee I, et al. MNRR1 (formerly CHCHD2) is a bi-organellar regulator of mitochondrial metabolism. Mitochondrion. 2015;20:43–51. doi: 10.1016/j.mito.2014.10.003
  41. Meng H, Yamashita C, Shiba-Fukushima K, et al. Loss of Parkinson’s disease-associated protein CHCHD2 affects mitochondrial crista structure and destabilizes cytochrome c. Nat Commun. 2017;8:15500. doi: 10.1038/ncomms15500
  42. Tio M, Wen R, Lim YL, et al. Varied pathological and therapeutic response effects associated with CHCHD2 mutant and risk variants. Hum Mutat. 2017;38(8):978–987. doi: 10.1002/humu.23234
  43. Scarffe LA, Stevens DA, Dawson VL, Dawson TM. Parkin and PINK1: much more than mitophagy. Trends Neurosci. 2014;37(6):315–324. doi: 10.1016/j.tins.2014.03.004
  44. Pickrell AM, Youle RJ. The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson’s disease. Neuron. 2015;85(2):257–273. doi: 10.1016/j.neuron.2014.12.007
  45. Pickrell AM, Huang CH, Kennedy S, et al. Endogenous Parkin preserves dopaminergic substantia nigral neurons following mitochondrial DNA mutagenic stress. Neuron. 2015;87(2):371–381. doi: 10.1016/j.neuron.2015.06.034
  46. Shin JH, Ko HS, Kang H, et al. PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson’s disease. Cell. 2011;144(5):689–702. doi: 10.1016/j.cell.2011.02.010
  47. Stevens DA, Lee Y, Kang HC, et al. Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration. Proc Natl Acad Sci U S A. 2015;112(37):11696–11701. doi: 10.1073/pnas.1500624112
  48. Lill CM. Genetics of Parkinson’s disease. Mol Cell Probes. 2016;30(6):386–396. doi: 10.1016/j.mcp.2016.11.001
  49. Pryde KR, Smith HL, Chau KY, Schapira AH. PINK1 disables the anti-fission machinery to segregate damaged mitochondria for mitophagy. J Cell Biol. 2016;213(2):163–171. doi: 10.1083/jcb.201509003
  50. Lee Y, Stevens DA, Kang SU, et al. PINK1 Primes Parkin-mediated ubiquitination of PARIS in dopaminergic neuronal survival. Cell Rep. 2017;18(4):918–932. doi: 10.1016/j.celrep.2016.12.090
  51. Geisler S, Holmström KM, Skujat D, et al PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol. 2010;12(2):119–131. doi: 10.1038/ncb2012
  52. Kondapalli C, Kazlauskaite A, Zhang N, et al. PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biol. 2012;2(5):120080. doi: 10.1098/rsob.120080
  53. Kazlauskaite A, Kondapalli C, Gourlay R, et al. Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65. Biochem J. 2014;460(1):127–139. doi: 10.1042/BJ20140334
  54. Kane LA, Lazarou M, Fogel AI, et al. PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J Cell Biol. 2014;205(2):143–153. doi: 10.1083/jcb.201402104
  55. Lazarou M, Sliter DA, Kane LA, et al. The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. Nature. 2015;524(7565):309–314. doi: 10.1038/nature14893
  56. Wang X, Winter D, Ashrafi G, et al. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell. 2011;147(4):893–906. doi: 10.1016/j.cell.2011.10.018
  57. Kostic M, Ludtmann MH, Bading H, et al. PKA phosphorylation of NCLX reverses mitochondrial calcium overload and depolarization, promoting survival of PINK1-deficient dopaminergic neurons. Cell Rep. 2015;13(2):376–386. doi: 10.1016/j.celrep.2015.08.079
  58. Amo T, Saiki S, Sawayama T, et al. Detailed analysis of mitochondrial respiratory chain defects caused by loss of PINK1. Neurosci Lett. 2014;580:37–40. doi: 10.1016/j.neulet.2014.07.045
  59. Park JS, Blair NF, Sue CM. The role of ATP13A2 in Parkinson’s disease: clinical phenotypes and molecular mechanisms. Mov Disord. 2015;30(6):770–779. doi: 10.1002/mds.26243
  60. Grünewald A, Arns B, Seibler P, et al. ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome. Neurobiol Aging. 2012;33(8):1843.e1–7. doi: 10.1016/j.neurobiolaging.2011.12.035
  61. Ramonet D, Podhajska A, Stafa K, et al. PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity. Hum Mol Genet. 2012;21(8):1725–1743. doi: 10.1093/hmg/ddr606
  62. Раrk JS, Koentjoro B, Veivers D, et al. Parkinson’s disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction. Hum Mol Genet. 2014;23(11):2802–2815. doi: 10.1093/hmg/ddt623
  63. Tsunemi T, Krainc D. Zn²+ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Hum Mol Genet. 2014;23(11):2791–2801. doi: 10.1093/hmg/ddt572
  64. Karuppagounder SS, Brahmachari S, Lee Y, et al. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson’s disease. Sci Rep. 2014;4:4874. doi: 10.1038/srep04874
  65. Dikic I, Bremm A. DUBs counteract parkin for efficient mitophagy. EMBO J. 2014;33(21):2442–2443. doi: 10.15252/embj.201490101
  66. Hamacher-Brady A., Brady N.R. Mitophagy programs: mechanisms and physiological implications of mitochondrial targeting by autophagy. Cell Mol Life Sci. 2016;73(4):775–795. doi: 10.1007/s00018-015-2087-8
  67. Koentjoro B, Park JS, Sue CM. Nix restores mitophagy and mitochondrial function to protect against PINK1/Parkin-related Parkinson’s disease. Sci Rep. 2017;7:44373. doi: 10.1038/srep44373
  68. Hayashi G, Jasoliya M, Sahdeo S, et al. Dimethyl fumarate mediates Nrf2-dependent mitochondrial biogenesis in mice and humans. Hum Mol Genet. 2017;26(15):2864–2873. doi: 10.1093/hmg/ddx167
  69. Linker RA, Gold R. Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects. Curr Neurol Neurosci Rep. 2013;13(11):394. doi: 10.1007/s11910-013-0394-8
  70. Kaidery NA, Banerjee R, Yang L, et al. Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson’s disease. Antioxid Redox Signal. 2013;18(2):139–157. doi: 10.1089/ars.2011.4491
  71. Johri A, Calingasan NY, Hennessey TM, et al. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington’s disease. Hum Mol Genet. 2012;21(5):1124–1137. doi: 10.1093/hmg/ddr541
  72. Li X, Wang H, Gao Y, et al. Quercetin induces mitochondrial biogenesis in experimental traumatic brain injury via the PGC-1α signaling pathway. Am J Transl Res. 2016;8(8):3558–3566.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Zhukova N.G., Kolobovnikova J.V., Sayfitdinkhuzhaev Z.F.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».